drugset
drugset / Trial / NCT06153355

A First-In-Human Study of LY3839840 in Healthy Participants

NCT06153355 ↗

Phase 1 Completed 140 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindBasic science

Summary

The main purpose of this first-in-human study to investigate the safety of LY3839840 in single and multiple doses, and how it's processed in the body when given in different amounts.

Timeline

Start
2023-12-04
Primary completion
2025-05-22
Completion
2025-05-22

Drugs

EvaluationDrugModalityDoseRoute
Subject LY3839840 Unknown — Oral
Background Midazolam Small molecule — Oral

Indications

No indication recorded.